Canterbury DHB


Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, FGFR1, or with PCM1-JAK2

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia5 separates CEL-NOS and HES from haematologic malignancies with eosinophilia associated with abnormalities of:

This is of major therapeutic relevance because imatinib is only effective in the presence of a PDGFR mutation.

About this Canterbury DHB document (6417):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 6417